中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.023 seconds)

    SP35 ANTIBODIES AND USES THEREOF
    2.
    发明申请
    SP35 ANTIBODIES AND USES THEREOF 审中-公开
    SP35抗体及其用途

    公开(公告)号：WO2008086006A3

    公开(公告)日：2008-11-06

    申请号：PCT/US2008000316

    申请日：2008-01-09

    Applicant: BIOGEN IDEC INC ,  MI SHA ,  PEPINSKY R BLAKE ,  SHAO ZHAOHUI ,  GARBER ELLEN A ,  MIKLASZ STEVEN D

    Inventor： MI SHA ,  PEPINSKY R BLAKE ,  SHAO ZHAOHUI ,  GARBER ELLEN A ,  MIKLASZ STEVEN D

    IPC: A61K31/70 ,  A61K38/16 ,  A61K39/395 ,  C07H21/00 ,  C07K14/00 ,  C07K16/00

    CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

    Abstract: Endogenous Sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous Sp35 function, such anti-Sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for Sp35, and methods of using such antibodies as antagonists of endogenous Sp35 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-Sp35 antibody.

    Abstract translation: 内源性Sp35是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节器。 阻断内源性Sp35功能的分子，例如抗Sp35抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供了特异于Sp35的抗体，以及使用这些抗体作为内源性Sp35功能的拮抗剂的方法。 本发明还提供了特异性杂交瘤和噬菌体文库衍生的单克隆抗体，编码这些抗体的核酸以及包含这些抗体的载体和宿主细胞。 本发明进一步提供了促进脊椎动物中少突胶质细胞存活和髓鞘形成的方法，包括向需要这种治疗的脊椎动物施用有效量的抗Sp35抗体。

    COMPOSITIONS COMPRISING ANTIBODIES TO LINGO OR FRAGMENTS THEREOF
    4.
    发明申请
    COMPOSITIONS COMPRISING ANTIBODIES TO LINGO OR FRAGMENTS THEREOF 审中-公开
    组合物包含抗体或其片段

    公开(公告)号：WO2010005570A3

    公开(公告)日：2010-04-29

    申请号：PCT/US2009003999

    申请日：2009-07-09

    Applicant: BIOGEN IDEC INC ,  MI SHA ,  PEPINSKY R BLAKE

    Inventor： MI SHA ,  PEPINSKY R BLAKE

    IPC: C07K16/28 ,  A61K39/395

    CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6849 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/01

    Abstract: Endogenous LINGO-I is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-I function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-I, and methods of using such antibodies as antagonists of endogenous LINGO-I function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.

    Abstract translation: 内源性LINGO-1是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节因子。 阻断内源性LINGO-1功能的分子，如抗LINGO-1抗体，可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供对LINGO-1特异性的抗体，以及使用这些抗体作为内源性LINGO-1功能拮抗剂的方法。 本发明还提供特异性杂交瘤和源自噬菌体文库的单克隆抗体，编码这些抗体的核酸，以及包含这些抗体的载体和宿主细胞。 本发明还提供了在脊椎动物中促进少突胶质细胞存活和髓鞘形成的方法，其包括对需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体。

    METHODS FOR PROMOTING MYELINATION, NEURONAL SURVIVAL AND OLIGODENDROCYTE DIFFERENTIATION VIA ADMINISTRATION OF SP35 OR TRKA ANTAGONISTS
    5.
    发明申请
    METHODS FOR PROMOTING MYELINATION, NEURONAL SURVIVAL AND OLIGODENDROCYTE DIFFERENTIATION VIA ADMINISTRATION OF SP35 OR TRKA ANTAGONISTS 审中-公开
    通过SP35或TRKA拮抗剂的管理促进血浆，神经营养和OLIGENENDROCYTE分化的方法

    公开(公告)号：WO2008013782A2

    公开(公告)日：2008-01-31

    申请号：PCT/US2007016589

    申请日：2007-07-24

    Applicant: BIOGEN IDEC INC ,  MI SHA ,  JUNG VINCENT

    Inventor： MI SHA ,  JUNG VINCENT

    IPC: A61K48/00

    CPC classification number: C07K14/71 ,  C07K14/705 ,  C07K2319/30

    Abstract: This invention relates to methods for promoting myelination, neuronal survival, and oligodendrocyte differentiation and treating demyelination and dysmyelination disease by the administration of a TrkA antagonist. The invention also relates to methods of inhibiting or decreasing Sp35 expression by the use of a TrkA antagonist. Additionally, the invention relates generally to methods for blocking Sp35 and TrkA interaction and inhibiting or decreasing TrkA phosphorylation by the administration of a Sp35 antagonist.

    Abstract translation: 本发明涉及通过施用TrkA拮抗剂来促进髓鞘形成，神经元存活和少突胶质细胞分化和治疗脱髓鞘和脱髓鞘疾病的方法。 本发明还涉及通过使用TrkA拮抗剂抑制或降低Sp35表达的方法。 此外，本发明一般涉及通过施用Sp35拮抗剂来阻断Sp35和TrkA相互作用并抑制或降低TrkA磷酸化的方法。

    COMPOSITIONS COMPRISING ANTIBODIES TO LINGO OR FRAGMENTS THEREOF
    9.
    发明申请
    COMPOSITIONS COMPRISING ANTIBODIES TO LINGO OR FRAGMENTS THEREOF 审中-公开
    包含抗体或其片段的组合物

    公开(公告)号：WO2010005570A2

    公开(公告)日：2010-01-14

    申请号：PCT/US2009/003999

    申请日：2009-07-09

    Applicant: BIOGEN IDEC MA INC. ,  MI, Sha ,  PEPINSKY, R., Blake

    Inventor： MI, Sha ,  PEPINSKY, R., Blake

    IPC: C07K16/28 ,  A61K39/395

    CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K47/6849 ,  A61K47/6879 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/35 ,  C07K2317/41 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/01

    Abstract: Endogenous LINGO-I is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-I function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-I, and methods of using such antibodies as antagonists of endogenous LINGO-I function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody.

    Abstract translation: 内源性LINGO-I是神经元存活，轴突再生，少突胶质细胞分化和髓鞘形成的负调节物。 阻断内源性LINGO-1功能的分子，例如抗LINGO-1抗体可用作治疗神经元和少突胶质细胞功能障碍的治疗剂。 本发明提供了特异于LINGO-1的抗体，以及使用这些抗体作为内源性LINGO-1功能的拮抗剂的方法。 本发明还提供了特异性杂交瘤和噬菌体文库衍生的单克隆抗体，编码这些抗体的核酸以及包含这些抗体的载体和宿主细胞。 本发明进一步提供了促进脊椎动物中少突胶质细胞存活和髓鞘形成的方法，包括向需要这种治疗的脊椎动物施用有效量的抗LINGO-1抗体。

Patent Agency Ranking